Evaluation of treatment response of cilengitide in an experimental model of breast cancer bone metastasis using dynamic PET with 18F-FDG
- 1 January 2011
- journal article
- research article
- Vol. 14 (1) , 15-20
Abstract
The purpose of this study was the assessment of the feasibility of dynamic positron emission tomography (PET) studies with fluorine-18 fluorodeoxyglucose (F-18-FDG) to quantify effects of the cyclic Arg-Gly-Asp peptide cilengitide, which targets the alpha v beta 3 and alpha v beta 5 integrin receptors in rats with breast cancer bone metastases. Rats were inoculated with MDA-MB-231 breast cancer cells, followed by the development of lytic lesions in the hind leg. Rats with lytic lesions were treated with cilengitide five times weekly on a continuous basis from days 30 to 55 after tumor cell inoculation. Dynamic PET studies with 18F-FDG were performed in untreated (n=9), controlled (n=4) and treated rats (n=6). The data were assessed using learning-machine two-tissue compartmental analysis. The F-18-FDG kinetic parameters obtained by two-tissue compartmental model learning-machine showed significant differences when individual parameters were compared between the control group and treated animals. Quantitative assessment of the tracer kinetics and the application of classification analysis to the data provided us with evidence to identify those tumors that demonstrated effect of cilengitide treatment. The transport rate K1 and the phosphorylation rate k3 were significantly different (P=0.033 and 0.038, respectively). Classification analysis based on support vector machines ranking feature elimination of the combination of PET parameters revealed an overall accuracy of 80.0% between treated animals and the control group. We were able to identify 83.3% treated animals compared with the control group based on k2 and VB. In conclusion, the results revealed that cilengitide treatment of experimental breast cancer bone metastases had a significant therapeutics impact on F-18-FDG kinetics.Keywords
This publication has 17 references indexed in Scilit:
- Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE‐MRI in a longitudinal in vivo studyInternational Journal of Cancer, 2010
- Novel anticancer targets: revisiting ERBB2 and discovering ERBB3Nature Reviews Cancer, 2009
- Imaging response to systemic therapy for bone metastasesEuropean Radiology, 2009
- Early effects of FOLFOX treatment of colorectal tumour in an animal model: assessment of changes in gene expression and FDG kineticsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008
- Characterization of a rat model with site‐specific bone metastasis induced by MDA‐MB‐231 breast cancer cells and its application to the effects of an antibody against bone sialoproteinInternational Journal of Cancer, 2005
- MicroPET imaging of breast cancer ?-integrin expression with Cu-labeled dimeric RGD peptidesMolecular Imaging and Biology, 2004
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Role of integrins in cell invasion and migrationNature Reviews Cancer, 2002